Completed PHASE4 INTERVENTIONAL 2-arm NCT00875082

Effect of Montelukast on Remodelling Markers in Asthmatic Children (MORACH)

Effect of Montelukast on Metalloproteinase (MMP)-9, MMP-12, Tissue Inhibitor Metalloproteinase-1 (TIMP-1), Procollagen Type I C-terminal Peptide (PICP) and TGF-beta1 Levels in Sputum From Mild Intermittent Asthmatic Children: a Pilot Study

Sponsor: Universita di Verona

Conditions Asthma

Interventions Montelukast placebo

Updated 5 times since 2017 Last updated: Jun 18, 2013 Started: Feb 28, 2010 Primary completion: Sep 30, 2011 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Asthma and is currently completed. Universita di Verona leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Universita di Verona

Data source: Universita di Verona

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Verona, Italy